Inbeeo

 🇺🇸𝗖𝗮𝘀𝗲 𝗦𝘁𝘂𝗱𝘆 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗨𝗦 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗳𝗼𝗿 𝗮 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝘁𝘆 𝗖𝗡𝗦 𝗖𝗹𝗶𝗲𝗻𝘁  🇺🇸 At Inbeeo, we partnered with a speciality CNS company to help them understand the pricing potential of their early-stage assets for the US market. Through a comprehensive approach, which included primary research and collaboration with an expert Advisory Board, we provided insights into US payer perceptions, key value drivers, and strategic positioning. Our efforts led to the identification of optimisation strategies for the client’s assets and informed a critical decision to advance one asset to Phase 2 clinical trials in a recommended indication. This project exemplifies our commitment to delivering actionable insights that drive smarter, more informed market access strategies. 💡 Curious to learn more? Please reach out to Sara Cueva Oemer or Enzo Straccia for the full case study and to discuss our bespoke solutions for your market access needs! #MarketAccess #CNS #PharmaStrategy #Inbeeo #PricingStrategy #ClinicalTrials #PrimaryResearch

🔍 𝗧𝗵𝗲 𝗣𝗼𝘄𝗲𝗿 𝗼𝗳 𝗮 𝗗𝘆𝗻𝗮𝗺𝗶𝗰 𝗩𝗮𝗹𝘂𝗲 𝗗𝗼𝘀𝘀𝗶𝗲𝗿 𝗶𝗻 𝗧𝗼𝗱𝗮𝘆’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲🌍 In the fast-paced world of healthcare, effectively communicating value—both internally and externally—has never been more crucial. 🚀 Our Inbeeo Consultant’ Tania Savant provides her thoughts on the ever-increasing need for compelling value dossier:  𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝗹𝗹𝘆: Understanding the specific needs of affiliates and regions is key. A one-size-fits-all approach simply does not cut it. By dynamically adapting a core value dossier, local teams are empowered to address their unique market demands, regulatory environments, and stakeholder expectations. 🌐 This tailoring ensures that every region can effectively demonstrate the value of the product in a way that resonates with local decision-makers. 🎯 𝗘𝘅𝘁𝗲𝗿𝗻𝗮𝗹𝗹𝘆: The landscape is becoming increasingly complex. Communicating value now requires keeping up with a diverse array of stakeholder perspectives. HTA bodies are moving beyond the payer perspective to include HCPs, patient preferences, and environmental and sustainability considerations into their decision-making. 🌱 Incorporating these factors into the value proposition is no longer just a ‘nice to have’—it is a necessity. ✅ Aligning value messaging with these evolving priorities is paramount. 📊 At Inbeeo, we provide our clients with more than just a dossier- we provide them with a comprehensive value toolkit which serves as a strategic document that can bridge the gap between global strategy and local execution, ensuring that the value story is heard, understood and acted upon by all who matter. 📩 To find out more about how Inbeeo can support your needs, please reach out to Tania Savant or Enzo Straccia! #HealthcareStrategy #ValueDossier #MarketAccess #Stakeholders 

🇫🇷 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: 𝗢𝘃𝗲𝗿𝗰𝗼𝗺𝗶𝗻𝗴 𝗗𝗮𝘁𝗮 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝗙𝗿𝗮𝗻𝗰𝗲'𝘀 𝗘𝗮𝗿𝗹𝘆 𝗔𝗰𝗰𝗲𝘀𝘀 𝗣𝗮𝘁𝗵𝘄𝗮𝘆𝘀 🇫🇷 With the 2021 reform of its early access programme, France has demonstrated remarkable dedication to addressing unmet medical needs. Over 250 early access applications were submitted, resulting in 95 approvals that benefited more than 100,000 patients. Notably, over half of these approvals were in the field of oncology, where there is a critical demand for innovative therapies. Impressively, 80% of these drugs have progressed to be reimbursed by national health insurance. https://lnkd.in/e5jzFgvT 💊💸 Early access represents a significant advancement for patients with limited therapeutic options, providing them with quicker access to innovative treatments supported by national solidarity. A crucial element of the early access programme reform is the requirement for comprehensive real-world data collection by manufacturers. This data is vital for several reasons: 1. Evaluating the safety and effectiveness of therapies. 2. Supporting the assessment of innovative medicines to secure permanent insurance coverage. 3. Researching and enhancing treatment adherence. 4. Informing future healthcare decisions with real-world evidence. However, the 2023 assessment by HAS and ANSM highlights significant challenges in this area. They identified concerns about the completeness and quality of the data collected. These issues often arise from administrative burdens, time-consuming procedures, and an insufficient understanding of objectives among healthcare professionals. Additionally, there are disparities in access to adequate staffing across regions, with some areas having optimal capacity and harmonised organisations, while others face workforce shortages. 🏥 Leem's white paper emphasises the need to simplify processes, improve transparency, and provide adequate funding for facilities. By addressing these challenges, we can strengthen France's position as a leader in early access to innovative therapies. https://lnkd.in/e5_ztNRk 🚀 France remains a champion of early access in Europe, offering numerous opportunities for pharmaceutical companies to bring their innovative assets to patients faster. However, it is crucial for companies to be mindful of these challenges and ensure proper data collection. 📈 Contributions by Sama Seyedmousavi, Senior Associate at Inbeeo. If you seek insights on early access and alternative pathways in France and Globally, please contact Vishal Yadav and Lucrezia Della Loggia at Inbeeo. Let’s continue to make strides in healthcare innovation together! 🌟 #EarlyAccess #HealthcareInnovation #RealWorldData #Pharma #MarketAccess #Datacollection

🤝𝗜𝗻𝗯𝗲𝗲𝗼 𝗶𝘀 𝗽𝗿𝗶𝘃𝗶𝗹𝗲𝗴𝗲𝗱 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝗺𝗮𝗿𝗸𝗲𝘁 𝗮𝗰𝗰𝗲𝘀𝘀 𝗹𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 ‘𝟮𝟬𝟮𝟰 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 𝗶𝗻 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘂𝗺𝗺𝗶𝘁’🤝 It was an honour for Inbeeo to host our recent ‘2024 Leaders in Access Virtual Summit’. Part of the Inbeeo aspiration is to provide a platform for industry peers to meet and discuss issues that affect so many of us working to improve access to innovative treatments. Inbeeo were proud to host seven senior Market Access leaders to offer up their unique perspectives, experiences and wisdom. The latest Summit’s two topics and ‘take homes’ being:  𝟭. 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗮𝗻𝗱 𝗛𝗲𝗮𝗹𝘁𝗵 𝗦𝘆𝘀𝘁𝗲𝗺 𝗣𝗼𝗹𝗶𝗰𝘆: o   Access policy is here to stay, and companies are striving to find the most effective way to organise it internally o   There is significant variation in organisational design, as well as in the levels of resourcing and funding allocated to access policy functions across different companies o   Hurdles to optimising the output of the function include raising internal awareness, clearly defining roles and responsibilities, and establishing performance metrics to measure impact both within the organisation and externally 𝟮. 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴 (𝗜𝗘𝗣): o   There are commonalities in the definition, structure and timing of IEP across companies, with consensus that initiation should commence as early as possible o   Internally, it is vital to incorporate cross-functional input and consider a multistakeholder perspective on an asset's value to ensure the success of IEP o   Significant challenges remain in terms of internal organisation, governance, and the ability to adapt priorities to meet the evolving demands of external stakeholders and market trends The Inbeeo team all agreed that our ‘2024 Leaders in Access Virtual Summit’ goals of connecting, building trust, and sharing were 100% met. On behalf of the Inbeeo team, a huge thank you to all the participants who were able to contribute to such a rich agenda and discussion! Much gratitude to Sylvie Grenêche, Diane Munch, Julie Spiesser, Pernille Storm, Elena Tricca, Eric Lechien, Daniel Jackson, and Keir Woods. For further information regarding the Inbeeo ‘2024 Leaders in Access Summit’ and to hear more about how we can support your market access needs, please do contact Enzo Straccia. #InbeeoLeadersInAccessSummi #Thoughtleadership #Pharmaceuticals #Accessstrategy #Marketaccess #Patientaccess #MarketAccess #PopulationHealth

🐾 𝗜𝗻𝗯𝗲𝗲𝗼’𝘀 𝘀𝘂𝗺𝗺𝗲𝗿 𝟮𝟬𝟮𝟰 𝗶𝗻𝘁𝗲𝗿𝗻 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲: 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝘂𝗽𝗱𝗮𝘁𝗲 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝘆𝗼𝘂𝗿 𝗱𝗮𝘆!🐾 Inbeeo are very proud of our heritage in providing work experience opportunities to those who are keen to join the world of Market Access! With this in mind, we are thrilled to introduce our newest summer recruit: Rocky! Rocky impressed us at his interview by demonstrating he is a perfect fit for Inbeeo: 🐶He has insatiable curiosity and enthusiasm 🦴He is adept at sniffing out opportunity 🐕He will always go the extra mile 🐾He never leaves anything on the table His paws of approval on our projects are exactly what we never knew we were missing. Welcome to our team, Rocky! 🌅Wishing everyone a great rest of the Summer!🌅 As we return from the Summer break, please do contact Enzo Straccia and Sama Seyedmousavi to discuss how the Inbeeo team can help with your Market Access and Pricing objectives! #TeamInbeeo #NewRecruit #OfficeDog #StrategicMarketAccess

💊 💡𝗜𝗥𝗔 𝗡𝗲𝗴𝗼𝘁𝗶𝗮𝘁𝗶𝗼𝗻 𝗢𝘂𝘁𝗰𝗼𝗺𝗲𝘀 & 𝗔𝗻𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲𝗱 𝗜𝗺𝗽𝗮𝗰𝘁𝘀💊 💡 -- Inbeeo Manager, Charlotte Langbo, provides thoughts on the recent IRA/industry pricing negotiation outputs -- The Inflation Reduction Act (IRA) is a historic US legislation intended to improve Medicare by enhancing benefits, decreasing drug costs, and improving the sustainability of the programme. For the first round of drug price negotiations, the Centers for Medicare & Medicaid Services (CMS) selected 10 of the top-spend Medicare Part D drugs, underwent pricing negotiations with manufacturers, and released the resulting maximum fair prices on August 15th, to be implemented at the start of 2026. 𝗔𝘁 𝗮 𝗵𝗶𝗴𝗵 𝗹𝗲𝘃𝗲𝗹, 𝘁𝗵𝗲 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝘄𝗲𝗿𝗲 𝗻𝗼𝘁 𝘀𝘂𝗿𝗽𝗿𝗶𝘀𝗶𝗻𝗴, 𝗯𝘂𝘁 𝗱𝗲𝗺𝗼𝗻𝘀𝘁𝗿𝗮𝘁𝗲: •   𝗚𝗿𝗲𝗮𝘁𝗲𝗿 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗼𝗻 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝘄𝗲𝗿𝗲 𝗳𝗲𝗹𝘁 𝘃𝘀. 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗶𝗻 𝘁𝗵𝗶𝘀 𝗶𝗻𝗶𝘁𝗶𝗮𝗹 𝗿𝗼𝘂𝗻𝗱 𝗼𝗳 𝗻𝗲𝗴𝗼𝘁𝗶𝗮𝘁𝗶𝗼𝗻𝘀 •   Despite some of the high face value price cuts (e.g., 79% off Januvia’s WAC), 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗮𝗿𝗲 𝗿𝗲𝗹𝗮𝘁𝗶𝘃𝗲𝗹𝘆 𝗶𝗻𝗰𝗿𝗲𝗺𝗲𝗻𝘁𝗮𝗹, given the expected steep rebates already in place and starting points set by CMS 𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗳𝗶𝗿𝘀𝘁 𝗿𝗼𝘂𝗻𝗱 𝗼𝗳 𝗻𝗲𝗴𝗼𝘁𝗶𝗮𝘁𝗶𝗼𝗻𝘀 𝗶𝗺𝗽𝗹𝘆 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲? •   Though initial drugs’ discounts are incremental, the subsequent rounds are expected to focus on medical benefits and oncology products, with potential to more severely reduce prices that are not already highly rebated •   The ripple impacts on the first round drugs’ competitors and bottom line remain uncertain •   The new pressure on this end of the supply chain may push PBMs and manufacturers to recover costs at other points in the supply chain, via new rebate structures, fees, etc.     Inbeeo will continue to monitor IRA negotiation announcements and support our clients through these uncharted implications with proactive strategic planning. Reach out to Enzo Straccia or Charlotte Langbo to learn more! Source: CMS Drug Price Negotiation Program (https://lnkd.in/gkvHYWWu) #InflationReductionAct #IRA #MaximumFairPrices #Diabetes #Oncology

🚀 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗻𝗲𝘄𝘀 𝗳𝗿𝗼𝗺 𝗜𝗻𝗯𝗲𝗲𝗼! 𝗪𝗲’𝗿𝗲 𝘁𝗵𝗿𝗶𝗹𝗹𝗲𝗱 𝘁𝗼 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝘀𝗼𝗺𝗲 𝘄𝗲𝗹𝗹-𝗱𝗲𝘀𝗲𝗿𝘃𝗲𝗱 𝗽𝗿𝗼𝗺𝗼𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵𝗶𝗻 𝗼𝘂𝗿 𝘁𝗲𝗮𝗺!🚀 🎉 John Ming Kei Lee has been promoted to 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁! Since joining us as an intern three years ago, John has become our go-to expert for market access, pricing, and quantitative analysis in Japan and China. His dedication and insights have made a lasting impact on our team and clients alike. We can't wait to see what he accomplishes next! 🌟 👏 Sama Seyedmousavi has been promoted to 𝗦𝗲𝗻𝗶𝗼𝗿 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲! Her unwavering commitment to market access and her readiness to tackle challenges head-on continue to inspire us all. We’re excited to watch her grow and excel in this new role! 🎉 Congratulations to Bart Strzelec on his promotion to 𝗦𝗲𝗻𝗶𝗼𝗿 𝗙𝗶𝗻𝗮𝗻𝗰𝗲 𝗮𝗻𝗱 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲! His implementation of streamlined processes/tools and continuous team training have empowered our project teams to excel in their consulting roles. He helps keep Inbeeo running like a well-oiled machine! Please join us in congratulating John, Sama, and Bart on their fantastic achievements! 👏 We're incredibly proud of our team's growth and excited for what the future holds. 🎖️ #TeamInbeeo #Leadership #CareerGrowth #TeamSuccess #EmployeeRecognition #Congratulations #Promotions #MarketAccess #Consulting #Finance #Operations

🔄💡💰𝗜𝘀 𝗣𝗮𝗿𝗮𝗹𝗹𝗲𝗹 𝗧𝗿𝗮𝗱𝗲 𝗕𝗲𝗶𝗻𝗴 𝗢𝘃𝗲𝗿𝗹𝗼𝗼𝗸𝗲𝗱 𝗶𝗻 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆?🔄💡💰 The 2024 EFPIA report (https://lnkd.in/dSwBrr-k) highlights that parallel trade reached an estimated value of €6,366 million at ex-factory prices in 2022. This is driven by the significant variations in pricing, reimbursement, and HTA procedures across Europe, and has led to notable challenges such as: •   𝗦𝘂𝗽𝗽𝗹𝘆 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗜𝗺𝗯𝗮𝗹𝗮𝗻𝗰𝗲𝘀: Diverted products often result in shortages, affecting patients' access to essential medicines. •   𝗥𝗶𝘀𝗸 𝗼𝗳 𝗙𝗮𝗹𝘀𝗶𝗳𝗶𝗲𝗱 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀: The lack of transparency can compromise patient safety. •   𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗜𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Parallel trade reduces the resources available for R&D and complicates pricing calculations for manufacturers. In 2022, Denmark was the most impacted market, with 29% of its pharmacy market sales coming from parallel imports, followed by Sweden at 11% and the UK at 10% (https://lnkd.in/eNr5kzpm). At Inbeeo, we recognise the complexities surrounding parallel trade and its impact on the pharmaceutical sector. Our expertise lies in helping businesses navigate these challenges, ensuring supply integrity, optimizing revenue, and integrating parallel trade considerations into International Reference Pricing (IRP) models. Contributions by Vishal Yadav, Senior Consultant at Inbeeo. If you are interested in exploring how we can support your pricing strategy and address the implications of parallel trade, do connect with us to see how we can help you! #Pharmaceuticals #ParallelTrade #Healthcare #PricingStrategy #IRP

🌟 𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝘁𝗼 𝘁𝗵𝗲 𝗧𝗲𝗮𝗺, 𝗔𝗻𝗱𝗿𝗲𝗮! 🌟 Inbeeo are happy to announce that Andrea O. has joined the team in our London office! Andrea brings a strong foundation in market access consulting, having collaborated with pharmaceutical and biotechnology companies to develop strategies to secure patient access for assets in oncology, dermatology, chronic, infectious, and rare diseases. Her project experience includes landscape assessments, price and reimbursement potential analyses, evidence gap analyses, and value communication tool development in Europe, Asia-Pacific, America, and Latin America. Andrea holds an MPhil in Bioscience Enterprise from the University of Cambridge and a BSc in Molecular Biology and Biotechnology from the University of the Philippines Diliman. Andrea’s scientific background, commercial acumen, and extensive project expertise are already making her an invaluable asset to our team. 🎉 Please join us in celebrating Andrea’s arrival at Inbeeo! 🎉 #welcome #newjoiner #marketacess #strategy #London

🔍𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗡𝗜𝗖𝗘 𝗴𝘂𝗶𝗱𝗮𝗻𝗰𝗲 𝗶𝗻𝘁𝗼 𝗹𝗼𝗰𝗮𝗹 𝗮𝗰𝗰𝗲𝘀𝘀: 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝘂𝗽𝘁𝗮𝗸𝗲 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗜𝗖𝗕𝘀🌟 Ensuring consistent uptake of NICE-approved medicines across different regions has been a key priority for NHS England (NHSE). However, financial and operational constraints on ICBs, as well as unique population demands, pose significant challenges. Pharma and MedTech manufacturers must consider several key strategies to optimise product uptake, including: 𝟭. 𝗗𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗞𝗲𝘆 𝗕𝗮𝗿𝗿𝗶𝗲𝗿𝘀 𝗮𝗻𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀: 🛑 Before addressing the variation in uptake, it is crucial to understand the specific barriers within local systems. At Inbeeo, we conduct thorough analyses to map out these challenges and identify region-specific opportunities, learning from past initiatives to inform our approach 𝟮. 𝗢𝗽𝘁𝗶𝗺𝗶𝘀𝗲𝗱 𝗦𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿 𝗩𝗮𝗹𝘂𝗲 𝗗𝗲𝗺𝗼𝗻𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻: 💡 Demonstrating value to all healthcare stakeholders involves accounting for patient preferences, understanding local healthcare provider perspectives, and having a thorough grasp of population health dynamics within each region. 𝟯. 𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻: 📊 Communicating evidence effectively is vital for driving informed decision-making. Our expertise lies in crafting compelling narratives that resonate with local payers and stakeholders. 𝟰. 𝗘𝗻𝗴𝗮𝗴𝗶𝗻𝗴 𝗞𝗲𝘆 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗮𝗸𝗲𝗿𝘀: 🤝 Building strong relationships with ICBs and NHS regional teams is key. We guide you in prioritising these engagements, ensuring that your product’s value is effectively communicated and understood by all relevant stakeholders. At Inbeeo, we have hands-on experience of transforming national reimbursement success into local-level adoption, ensuring your innovations reach the patients who need them most. Let’s work together to navigate these challenges and achieve consistent, system-wide success. 📩 To find out more about how Inbeeo can support your needs, please reach out to Tania Savant or Enzo Straccia #MarketAccess #NICEReimbursement #ICS #Healthcare #Pharmaceuticals #PayerStrategy #ValueDemonstration #EvidenceCommunication